On Invalid Date, Benitec Biopharma (NASDAQ: BNTC) reported Q1 2023 earnings per share (EPS) of -$0.00, up 50% year over year. Total Benitec Biopharma earnings for the quarter were -$4.40 million. In the same quarter last year, Benitec Biopharma's earnings per share (EPS) was -$0.00.
As of Q2 2023, Benitec Biopharma's earnings has grown year over year. Benitec Biopharma's earnings in the past year totalled -$19.97 million.
What was BNTC's revenue last quarter?
On Invalid Date, Benitec Biopharma (NASDAQ: BNTC) reported Q1 2023 revenue of $54.00 thousand up 12.5% year over year. In the same quarter last year, Benitec Biopharma's revenue was $48.00 thousand.
What was BNTC's revenue growth in the past year?
As of Q2 2023, Benitec Biopharma's revenue has grown -9.33% year over year. This is 78.87 percentage points lower than the US Biotechnology industry revenue growth rate of 69.53%. Benitec Biopharma's revenue in the past year totalled $68.00 thousand.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.